LENZ Therapeutics Inc (LENZ) Actualités

LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the...

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug...

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the...

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater...

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial...

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive...

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100...

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 424B3 - Prospectus [Rule 424(b)(3)]